Evidence supporting the use of SGLT2 inhibitors in patients with severe CKD is limited due to increased risks of adverse reactions like diabetic ketoacidosis, hypovolemia, and acute kidney injury in diabetic patients, making it often contraindicated in those with severe renal insufficiency (GFR <30 mL/min/1.73 m2) (Qiu et al., 2021). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.